Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC By Ogkologos - March 17, 2025 546 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Could Cholesterol-Lowering Drugs Improve Cancer Immunotherapy? December 10, 2020 Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian Cancers May 4, 2018 EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib March 27, 2026 Can Acupuncture Help Cancer Survivors with Chronic Pain? April 22, 2021 Load more HOT NEWS Durvalumab Extends Lives of People with Early-Stage Small Cell Lung Cancer Long-Term Efficacy of Single-Agent Neoadjuvant/Adjuvant PD1 Blockade for Resectable Cutaneous Melanoma... Addressing Common Concerns Around Taking Opioids for Cancer-Related Pain: An Expert... Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected...
